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Background: Recent outbreaks of measles and polio in low-income countries illustrate that conventional methods
for estimating vaccination coverage do not adequately identify susceptible children. Immune markers of protection
against vaccine-preventable diseases in oral fluid (OF) or blood may generate more accurate measures of effective
vaccination history, but questions remain about whether antibody surveys are feasible and informative tools for
monitoring immunization program performance compared to conventional vaccination coverage indicators. This
study compares six indicators of measles vaccination status, including immune markers in oral fluid and blood, from
children in rural Bangladesh and evaluates the implications of using each indicator to estimate measles vaccination
coverage.
Methods: A cross-sectional population-based study of children ages 12–16 months in Mirzapur, Bangladesh,
ascertained measles vaccination (MCV1) history from conventional indicators: maternal report, vaccination card
records, ‘card + history’ and EPI clinic records. Oral fluid from all participants (n = 1226) and blood from a subset
(n = 342) were tested for measles IgG antibodies as indicators of MCV1 history and compared to conventional
MCV1 coverage indicators.
Results: Maternal report yielded the highest MCV1 coverage estimates (90.8%), followed by EPI records (88.6%), and
card + history (84.2%). Seroprotection against measles by OF (57.3%) was significantly lower than other indicators,
even after adjusting for incomplete seroconversion and assay performance (71.5%). Among children with blood
results, 88.6% were seroprotected, which was significantly higher than coverage by card + history and OF serostatus
but consistent with coverage by maternal report and EPI records. Children with vaccination cards or EPI records
were more likely to have a history of receiving MCV1 than those without cards or records. Despite similar MCV1
coverage estimates across most indicators, within-child agreement was poor for all indicators.
Conclusions: Measles IgG antibodies in OF was not a suitable immune marker for monitoring measles vaccination
coverage in this setting. Because agreement between conventional MCV1 indicators was mediocre, immune marker
surveillance with blood samples could be used to validate conventional MCV1 indicators and generate adjusted
results that can be compared across indicators.
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Surveillance of vaccination coverage is important for dis-
ease control, monitoring health system performance, and
as a benchmark for progress toward Millennium Develop-
ment Goal 4 on reducing child mortality [1-3]. However,
conventional vaccination coverage estimates based on ad-
ministrative records or household surveys are at risk of
unintentional and intentional errors of omission, recording
and recall [4-11]. Financial incentives for improving co-
verage can exacerbate these biases [11]. Administrative re-
cords from Expanded Programme on Immunisation (EPI)
vaccination clinics generate vaccination coverage estimates
in real-time with little added cost, but can suffer significant
biases if reporting is incomplete or the eligible population
size is not accurately measured [10,12-14]. Household sur-
veys, such as the Demographic and Health Surveys (DHS)
or Multiple Indicator Cluster Survey (MICS), generate
three vaccination coverage indicators based on: 1) mater-
nal report, 2) household-retained vaccination cards, or 3) a
composite ‘card + history’ indicator, which uses vaccination
card data or, if not available, maternal report. The ‘card +
history’ indicator is regarded as the best available data
source balancing accuracy with completeness but surveys
are expensive and do not generate coverage estimates
in real-time [6,7,15-17]. Consequently, comparisons of
vaccination coverage using different indicators are
often invalid [4-6,10-12].
Recent outbreaks of measles in low-income countries
highlight that conventional vaccination coverage indica-
tors do not adequately identify susceptible children. There
is increasing interest in immune marker surveillance to
monitor immunization programs and estimate population
immunity attributable to vaccination [18-20]. However,
immune marker surveillance with blood or oral fluid (OF)
samples pose other errors and biases related to sample
collection, storage, testing and interpretation of results as
well as financial and logistical challenges in the field [21].
In this study, we compared six indicators of measles vac-
cination status, including immune markers of measles im-
munity in oral fluid and blood, from young children in
rural Bangladesh and evaluated the implications of using
each indicator to estimate measles vaccination (MCV1)
coverage.
Methods
The study was conducted among children aged 12–
16 months residing in the Mirzapur Demographic
Surveillance System (DSS), a rural area 60 km north of
Dhaka, Bangladesh. The DSS is comprised of ~240,000
individuals living in 58,300 households visited every
4 months to update births, deaths and migrations. A
stratified random sample of 1450 children was selected
from the eight unions (administrative unit similar to a
county) of the DSS with probability of proportional toeligible population size in each union. Ethics commit-
tees at the International Centre for Diarrhoeal Disease
Research, Bangladesh (icddr,b) and the Johns Hopkins
Bloomberg School of Public Health approved the study
and written permission from the participants’ guardian
was obtained prior to enrollment.
Data collection took place in three stages: a caregiver
survey and oral fluid collection in the household, review
of EPI clinic records, and blood collection from a subset
of children in four of the eight unions. A wealth index was
generated using principal component analysis based on
household assets [22]. Record books from EPI clinics were
obtained and records were matched to enrolled children
based on EPI registration IDs from their vaccination cards
or by matching at least three variables: child name, birth
date (±3 days), father’s name or grandfather’s name.
OF samples were obtained by rubbing a foam swab
(Oracol; Malvern Medical Developments, Worcester, UK)
along the child’s gumline for 1–1.5 minutes as described
elsewhere [23]. OF samples were transported in cold boxes
within 4 hours to the local laboratory where 1 mL of
transport buffer was added, centrifuged at 2000 rpm for
five minutes, and the supernatant was stored at -20°C until
testing. OF samples were tested for antibodies to measles
virus using a measles virus-specific IgG capture enzyme
immunoassay (ELISA) (Microimmune Ltd, Middlesesex,
UK), which was validated for use with OF samples with
a reported sensitivity of 93% and specificity of 98%
compared to serum [24]. OF samples were categorized as
positive, equivocal or negative; equivocal samples were
retested and, if equivocal again, were considered positive
in binary analyses. To identify poor quality OF samples,
specimens testing negative for measles IgG were tested
for total IgG antibodies by ELISA (Bethyl Laboratories,
Montgomery, TX) and excluded from the analysis if less
than 125 ng/mL.
Peripheral blood samples were collected by trained
phlebotomists from all enrolled children with parental
permission within one month of OF collection in four of
eight unions. Serum samples were extracted and stored
at -20°C until tested for measles IgG antibodies (Enzygnost
ELISA, Siemens, Germany) with a reported sensitivity and
specificity of 99.6% and 100%, respectively [25]. Serum
samples were categorized as negative, equivocal or positive
as recommended by the manufacturer. Serum samples
testing equivocal were re-tested and, if equivocal again,
were categorized as positive.
Up to six indicators of MCV1 history were ascertained
for each child: 1) maternal report of MCV1 based on re-
call questions modified from the DHS [26]; 2) card record
of MCV1 based on evidence and dates of MCV1 receipt
on the child’s household retained vaccination card, if avail-
able; 3) ‘card + history’; 4) EPI record of MCV1 based on
dates and evidence of MCV1 abstracted from EPI clinic
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bodies in OF; and 6) protective levels of measles IgG anti-
bodies in blood. MCV1 coverage by OF was adjusted for
assay sensitivity and specificity using following equation:
Padjusted = (Pobserved – (1-specificity))/(1 – [(1-specificity) +
(1-sensitivity)]). Seroprotection in OF and blood was as-
sumed to be vaccine induced because maternal antibodies
should have been non-detectable is this age group and the
last measles outbreak in the district occurred more
than a year before study participants were born according
to the WHO measles surveillance laboratory in Dhaka,
Bangladesh [27,28]. Study participants were not age eli-
gible for the 2010 MCV campaign.
Categorical variables were compared using chi-square
tests or Fisher’s exact test and continuous variables
with non-normal distributions were compared using the
Wilcoxon rank sum test. MCV1 coverage estimates were
generated with exact binomial confidence intervals and
compared using McNemar’s test for paired samples. Bi-
variate logistic and log binomial models were used to cal-
culate odds ratios and prevalence ratios, respectively.
Sensitivity, specificity and kappa were calculated to evalu-
ate within-child agreement of indicators. Analysis was con-
ducted in Stata 11 (StataCorp LP, College Park, TX, USA).
Results
1450 children were randomly selected from the DSS data-
base, of whom 1389 were living in the DSS area at the timeRandomly selected
(n=1389)1
Enrolled (n= 1260) 
Oral fluid (OF) collected 
(n= 1,259)
Not enrolled (n=129) 
Absent (n=78) 
 Age>16 mo. at visit (n=44) 
 Other (n=7)
Refused OF collection 
(n=1)
10% 
OF & serum analyzed2
(n= 330) 
Poor quality samples 
(n=33) 




Figure 1 Enrollment chart. 1 61 children selected from the database wer
study. 2 Blood samples were collected and analyzed from 342 children. Paiof the study. Of these children, 1260 (89.8%) were en-
rolled in the study from September 2010 to January 2011
(Figure 1, Additional file 1: Table S1). The parent of one
child refused OF collection and 33 OF samples were ex-
cluded for poor quality (total IgG antibodies <125 ng/mL),
resulting in 1226 children in the primary analysis. Vaccin-
ation records from EPI record books were found for 913
(72.5%) children, of whom 891 had an adequate OF sam-
ple. Blood was collected from 342 children with a 7.7% re-
fusal rate. Of children with blood sample results, 311
(91%) had adequate OF samples and 268 (78%) had EPI
clinic records.
No differences in the age, sex, asset quintile, house-
hold size, or education level of the father was observed
for enrolled versus non-enrolled children, but mothers
with more education (unadjusted OR 0.94 for each
additional year; 95% CI: 0.89, 0.99), working mothers
(OR 0.38; CI: 0.21, 0.68), and families that had moved at
least once since 2005 (OR 0.47; CI: 0.32, 0.68) were sig-
nificantly less likely to be enrolled.
Factors associated with MCV1 history
The mean age of enrolled children was 14.5 months with
an equal proportion of males and females (Table 1). Using
the card + history indicator as the best available data
source, MCV1 coverage did not differ by age or sex, but
children taken by family members other than the mother
for vaccination were less likely to have received MCV1. 
EPI Clinic Records 
(n= 913) 
EPI record not found 
(n=346)
OF & EPI Clinic Records
(n= 891) 
27.5% 
e not included because they migrated out of DSS before initiation of
red OF and blood samples were available for 330 children.
Table 1 Characteristics of enrolled children and factors associated with receipt of MCV1
Card + History indicator
Overall Vaccinated Unvaccinated
Frequency % (1033 children) (193 children) p-value1
Age at enrollment, mean (SD) 14.5 (1.4) 14.5 (1.5) 14.5 (1.4) 0.930
Male 628 51.2 534 (51.7) 94 (48.7) 0.446
Father’s education, median [IQR] (years) 7 [5, 9] 7 [5, 10] 5 [0, 9] <0.001
Mother’s education, median [IQR](years) 7 [4, 9] 7 [5, 9] 5 [2, 8] <0.001
Mother had job in last 3 years 154 12.6 116 (11.2) 38 (19.7) 0.001
Asset quintile (2010)2
1 - poorest 246 20.1 192 (18.6) 54 (28.0) 0.001
2 250 20.4 202 (19.6) 48 (24.9)
3 246 20.1 208 (20.1) 38 (19.7)
4 243 19.8 215 (20.8) 28 (14.5)
5 - wealthiest 241 19.7 216 (20.9) 25 (13.0)
Retained child's vaccination card 1019 83.1 872 (84.4) 147 (76.1) 0.005
Mother responsible for bringing child for vaccinations 1060 86.5 903 (87.4) 159 (79.9) 0.006
Location of child’s delivery3
Hospital or clinic 460 37.5 402 (38.9) 58 (30.0) 0.034
House (own, family or friend’s home) 752 61.3 621 (60.1) 131 (67.9)
Person assisting with child's delivery3
Qualified doctor 283 23.1 253 (24.5) 30 (15.4) 0.029
Skilled birth attendant 209 17.0 178 (17.2) 31 (16.1)
Traditional birth attendant 73 54.9 554 (53.6) 119 (61.7)
Other (mother, informal health worker, alone) 47 3.8 38 (3.7) 9 (4.7)
Antenatal care visits3
None 320 26.1 251 (24.3) 69 (35.8) <0.001
1 246 20.1 203 (19.6) 43 (22.3)
2 or more 645 52.6 568 (55.0) 77 (39.9)
Postnatal care visits3
None 645 52.6 525 (50.8) 120 (62.2) 0.007
1 412 33.6 364 (35.2) 48 (24.9)
2 or more 155 12.6 134 (13.0) 21 (10.9)
1Chi-square or Fisher’s exact test for categorical variables. Wilcoxon rank sum test for non-normal continuous variables.
2Asset quintiles calculated using principal component analysis from household asset data.
3Data on child’s delivery (n = 14), antenatal care (n = 15) and postnatal care (n = 14) not available for small number of children.
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tiles was associated with receipt of MCV1. Children vacci-
nated against measles were more likely to be born in a
hospital or clinic, have a skilled birth attendant or doctor
assist in their delivery, and have more antenatal and post-
natal care visits than unvaccinated children (Table 1).
MCV1 Coverage by indicator
Maternal report yielded the highest coverage estimates
(90.8% CI: 89.0, 92.3), followed by EPI records (88.6%;
CI: 86.3, 90.6), card records among card holders (85.6%;
CI: 83.3, 87.7), and card + history (84.2%; CI: 82.1, 86.2).Coverage of protective levels of measles IgG antibodies
in OF (57.3%; CI: 54.5, 60.1) was significantly lower than
conventional indicators (Figure 2). Two adjustments
were made to the raw OF prevalence to account for dif-
ferences between vaccination history and immunologic
status. Assuming 85% seroconversion among children
ages 9–10 months, MCV1 coverage by OF was 67.4%
(i.e. 57.3/0.85 = 67.4%) [29]. A subsequent adjustment
accounting for the reported sensitivity and specificity of
the assay generated a final adjusted MCV1 coverage es-
timate of 71.5% by OF, which remained statistically sig-
nificantly lower than coverage based on all conventional
Figure 2 Overall MCV1 Coverage by Indicator. Note: MCV1 coverage based on all available data and sample size varies by indicator. ‘Oral fluid
adjusted for seroconversion’ assumes 85% of vaccinated children seroconverted. ‘Oral fluid, adjusted for seroconversion and assay sensitivity/
specificity’ assumes 85% seroconversion and adjusts for the sensitivity (93%) and specificity (98%) of the assays, as reported by the manufacturer.
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wise tests) (Figure 3). For the 342 children with blood
results, 83.0% had protective levels of measles IgG anti-
bodies, 11.2% were susceptible and 5.8% had equivocal
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Figure 3 Measles vaccination coverage by indicator among subgroup
is not representative of the population because ~27% of records could not
population (n = 330 except for EPI clinic records where n = 268).analyses for an overall prevalence of 88.6% (CI: 85.2,
92.0). For children with both blood and OF samples,
MCV1 coverage by blood serostatus was significantly
higher than by card + history (84.5%, McNemar’s test
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s of children with complete data. Note: Coverage from EPI records
be located. Children with blood samples represent a subset of study
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(86.0%, p = 0.16).
To account for missing data for several indicators,
MCV1 coverage indicators were compared within sub-
groups of children who had complete data (Figure 3).
Within each subgroup, MCV1 coverage based on OF was
significantly lower than all other coverage indicators (p <
0.001 for all pairwise tests). MCV1 coverage by maternal
report was consistently higher than other indicators (p <
0.001 for all pairwise tests) except among those with both
blood and OF samples. To capture systematic differences
between indicators, prevalence ratios comparing MCV1
coverage for each pair of indicators were generated to
show the observed over- or under-estimation in MCV1
coverage estimates (Table 2).
83% of parents showed their child’s vaccination card at
the interview, of which 85.6% (CI: 83.4, 87.7) had evi-
dence of MCV1 on the card (Figure 3). Children with
vaccination cards were significantly more likely to have
received MCV1 than children without cards by all con-
ventional indicators and blood serostatus (maternal re-
port: 93.4% (card) vs. 77.8% (no card), p < 0.001; EPI
records: 86.9% vs. 100%, p = 0.006; OF: 58.6% vs. 51.2%,
p = 0.054; blood: 90.5% vs. 77.8%, p = 0.02). EPI records
were located for 72.5% of enrolled children. Children
with available EPI records were more likely to be youn-
ger, have lower asset scores, not moved since the child
was born, and retained the child’s vaccination card than
children whose records were not located (Table 3). Chil-
dren with EPI records had significantly higher MCV1
coverage by maternal report (93.5% with EPI records vs.
83.6% without EPI records, p < 0.001), card + history
(86.4% vs. 78.5%, p = 0.001), and blood serostatus (90.7%
vs. 80.6%, p = 0.041).Table 2 Prevalence ratios for MCV1 coverage to adjust for dif
vaccination coverage indicators
Comparison indicator











Note: Estimates are prevalence ratios [95% confidence intervals] to estimate the de
based on comparison indicator (row) divided by reference indicator (column). E.g. t
(PrR: 1.077 = 0.9078/0.8426) than coverage estimated by card + history. Bold indicat
presented as an example of a tool governments or EPI programs could develop toHigher asset quintiles were associated with higher
MCV1 coverage for all indicators except card records and
EPI records with the most substantial gap between the
bottom 20% and top 80% of asset scores (Table 4). The
relative odds of MCV1 history by maternal report was
2.41 times greater than for children in the top 80% of asset
scores (CI: 1.59, 3.65). Restricting analyses to children with
blood data attenuated differences across asset quintiles for
all indicators except coverage based on blood serostatus.
Children in the highest 80% of asset scores had signifi-
cantly higher odds of having protective levels of measles
IgG antibodies in blood than children in the lowest 20%
(OR 2.48; CI: 1.23, 5.01), whereas there was no difference
for maternal report (OR 1.77; CI: 0.79, 3.94), card + history
(OR 1.31; CI: 0.67, 2.57), or EPI records (OR 0.90; CI: 0.40,
1.99) (Table 4). Significant differences in measles serosta-
tus remained between the poorest quintile and other quin-
tiles after adjusting for MCV1 history (card + history) (OR
2.74; CI: 1.10, 6.90).
Agreement & performance of MCV1 indicators at
individual level
We also assessed within-child agreement for each data
source. MCV1 history by OF had poor sensitivity (62.3%;
CI: 59.3, 65.3) and specificity (69.4%; CI: 62.4, 75.8) com-
pared to card + history, which was considered the gold
standard. Maternal report had high sensitivity (99.4%;
CI: 98.7, 99.8) but poor specificity (55.4%; CI: 48.1, 62.6)
(Additional file 1: Table S2). To assess agreement between
maternal report and card records, the analysis was re-
stricted to children with vaccination cards. 99% of mothers
with card-confirmed MCV1 reported MCV1 history. For
those without card-confirmed MCV1, 43% still reported
MCV1 history, resulting in 91% agreement and a kappa offerences between indicators: an approach to comparing
Prevalence ratio [95% CI]
Card + History EPI records Serum
0.954 0.952 –
[0.914, 0.996] [0.893, 1.015]





gree of over- or underestimation for each method used. The prevalence ratio
he maternal report indicator generates an MCV1 coverage estimate 7.7% higher
es statistical significance with a 5% two-sided alpha. Results from this study are
compare vaccination coverage estimates from different indicators.
Table 3 Characteristics of children with and without EPI clinic records
EPI records found (n = 913) EPI records not found (n = 346)
Frequency % Frequency % p-value1
Age at enrollment (months), mean (SD) 13.8 (1.4) 14.0 (1.4) 0.026
Male 456 50.0 186 53.8 0.227
Father’s Education, in years, median (IQR) 6 [4, 9] 8 [5, 10] <0.001
Moved since child’s birth 327 35.8 163 47.1 <0.001
Asset quintile
1 (poorest) 198 21.7 55 15.9 0.001
2 191 20.9 61 17.6
3 177 19.4 75 21.7
4 189 20.7 62 17.9
5 (wealthiest) 158 17.3 93 26.9
Retained vaccination card 800 87.6 246 71.1 <0.001
History of MCV1 by maternal report 853 93.4 287 83.0 <0.001
History of MCV1 by card + history 790 87 270 78 <0.001
Fully vaccinated, by card + history 657 72.0 187 54.0 <0.001
Union
Ajgana 139 15.2 67 19.4 <0.001
Bahuria 146 16.0 25 7.2
Banail 104 11.4 14 4.0
Bhatgram 108 11.8 20 5.8
Gorai2 98 10.7 114 33.0
Jamurki 101 11.1 45 13.0
Uarsi 116 12.7 12 3.5
Mirzapur 101 11.1 49 14.1
1Chi square test for categorical variables. Wilcoxon rank sum test for non-normally distributed continuous variables.
2Record books from two EPI clinics in Gorai were not available.
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maternal report. 150 children had vaccination cards but
lacked evidence of MCV1 receipt on their card. Among
the 150, 105 (70%) had a date of MCV1 receipt in the
EPI record books, 86 (57%) mothers reported the child
received MCV1, and 67 (45%) had both. 43 of the 150
children had blood results, of which 25 (58%) were sero-
positive and only 18 (42%) were seronegative as expected
from their vaccination card.
Similarities in coverage at the population level often
masked discordance between indicators. Among children
with both vaccination cards and EPI records, MCV1
coverage was the same by EPI record or vaccination card
but within-child agreement was only 73.8% (CI: 70.6, 76.8)
because an equal number of children were positive by one
source and negative by the other (Table 5).
Discussion
Using surveys, clinic records and immunologic markers,
up to six measures of MCV1 coverage were generated for
a representative sample of children in rural Bangladesh.No prior study has compared as many indicators including
immune markers from a single cohort of children. Apart
from OF results, vaccination coverage estimates did not
vary dramatically across data sources or indicators. MCV1
coverage from reported or recorded data ranged from 84%
to 91%, with a best estimate of 84% based on the ‘gold
standard’ card + history indicator. A 2010 Bangladesh gov-
ernment survey using the card + history indicator found
84% MCV1 coverage for the district, a catchment area
slightly larger than the DSS [30].
Immune marker surveillance with OF was not an accur-
ate indicator of vaccination history compared to all other
indicators. The proportion of children with detectable anti-
bodies in OF was significantly lower than expected by re-
ported or recorded MCV1 coverage even after adjusting
for incomplete seroconversion and assay performance [29].
In the subset of children with blood samples, poor agree-
ment between blood and OF results reinforced that OF
testing was not an accurate immune marker and is not rec-
ommended for use in immunization surveillance unless the
validity and reliability of OF testing can be improved [31].
Table 4 Association between indicators of MCV1 coverage and socioeconomic status
All children in study (n = 1226)
Asset quintile Total p-value2
1 – poorest 2 3 4 5 - wealthiest
Maternal recall (n = 1226)1 83.7 88.0 93.1 95.1 94.2 90.8
(78.4, 88.1) (83.3, 91.8) (89.2, 95.9) (91.5, 97.4) (90.4, 96.8) (89.0, 92.3) <0.001
Card + History (n = 1226)1 78.0 80.8 84.6 88.5 89.6 84.2 0.003
(72.3, 83.1) (75.4, 85.5) (79.4, 88.8) (83.8, 92.2) (85.1, 93.2) (82.1, 86.2)
Card record (n = 1046) 82.8 84.7 84.8 86.7 89.4 85.7
(77.0, 87.6) (79.1, 89.3) (79.4, 89.2) (81.2, 91.1) (84.4, 93.2) (83.4, 87.7) 0.135
Oral fluid (n = 1226)1 49.2 55.2 60.6 61.7 60.2 57.3
(42.8, 55.6) (48.8, 61.5) (54.2, 66.7) (55.3, 67.9) (53.7, 66.4) (54.5, 60.1) 0.004
EPI records (n = 913) 87.9 89.0 88.7 91.0 84.8 88.4
(82.5, 92.1) (83.7, 93.1) (83.1, 93.0) (86.0, 94.6) (78.2, 90.0) (86.1, 90.4) 0.25
% of EPI records found 78% 76% 70% 75% 63% 73%
Children with blood samples (n = 342)
1 - poorest 2 3 4 5 - wealthiest Total p-value2
Maternal recall (n = 342) 86.8 87.3 92.7 93.8 94.7 90.9
(77.1, 93.5) (77.3, 94.0) (82.4, 98.0) (84.8, 98.3) (87.1, 98.5) (87.4, 93.8) 0.163
Card + History (n = 342) 81.6 74.6 85.5 87.5 93.4 84.5
(71.0, 89.5) (62.9, 84.2) (73.3, 93.5) (76.8, 94.4) (85.3, 97.8) (80.2, 88.2) 0.425
Card record (n = 294)1 82.1 78.3 86.3 88.0 92.4 85.4
(70.8, 90.4) (65.8, 87.9) (73.7, 94.3) (75.7, 95.5) (83.2, 97.5) (80.8, 89.2) 0.388
Oral fluid (n = 330)1 50.7 52.8 54.7 61.7 55.4 54.8
(38.7, 62.6) (40.6, 64.9) (40.4, 68.4) (48.2, 73.9) (43.4, 67.0) (49.3, 60.3) 0.418
Serum (n = 342) 80.2 90.1 89.1 90.6 93.4 88.6
(69.5, 88.5) (80.7, 95.9) (77.8, 95.9) (85.3, 98.9) (85.3, 97.8) (85.2, 92.0) 0.011
EPI records (n = 278)1 87 89.6 91.3 88.4 73.6 86
(76.7, 93.8) (78.8, 96.1) (79.2, 97.6) (76.6, 95.6) (59.7, 84.7) (81.3, 89.8) 0.786
% of EPI records found 91% 82% 84% 82% 70% 81%
1 Restricted analysis to children with serum and vaccination card records (n = 294), adequate OF samples (n = 330), or EPI records (n = 278).
2 Z-test comparing quintile 1 vs. quintiles 2–5.
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natal, delivery and postnatal care in the formal health sys-
tem were more likely to have MCV1 vaccinated children.
Unlike some other studies from South Asia, boys were
not more likely than girls to be vaccinated with MCV1
[32,33]. Unvaccinated children were more likely to live in
households with relatively lower SES and education. After
accounting for reported vaccination history, children inTable 5 Discordance between MCV1 history in EPI records
& vaccination cards
Vaccination card
MCV1 (+) MCV1 ( − )
EPI MCV1 (+) 694 105
records MCV1 (−) 105 1
Note: Includes only children with vaccination card records and EPI clinic
records (n = 800).the poorest 20% were significantly more likely to be mea-
sles susceptible than those in the upper 80%, warranting
further investigation into biological or systems-level causes
of susceptibility among the very poor [34,35].
Many studies have shown that reported and recorded
vaccination history data are fraught with biases and
errors in recall and omission [4,6,8,11,16,36,37]. Studies in
Bangladesh [38], Costa Rica [9], and England [39] found
that maternal report inflated coverage estimates but our
results illustrated that maternal report or card + history
indicators performed well compared to serological and
government estimates of MCV1 coverage. Without a gold
standard of vaccination history, it was not possible to as-
sess if maternal report overestimated coverage. What may
be more important is to generate vaccination coverage es-
timates that can be compared across indicators. Currently
policymakers frequently compare vaccination coverage
Hayford et al. BMC Public Health 2013, 13:1211 Page 9 of 10
http://www.biomedcentral.com/1471-2458/13/1211estimates generated from different indicators and data
sources, resulting in an ‘apples to oranges’ comparison.
Table 2 presents an example of how adjustment factors
could be generated for each pair of coverage indicators to
evaluate the degree of over- or underestimation with each
indicator. Because the indicators used in this study were
generated in the same way as national coverage estimates
from administrative records, coverage evaluation surveys
and DHS surveys, a similar table of adjustment factors
could be generated from a small representative sample of
children in a country and then used to adjust national
coverage estimates to make them more comparable be-
tween data sources.
Our results called into question whether vaccination
card records should be considered the best available infor-
mation for a child’s vaccination status because missing
vaccination records on the card could be verified with
other data sources. DHS and MICS surveys seek maternal
report of vaccination history only when the child’s vaccin-
ation card is not available. Future studies should explore if
vaccination history by maternal report should also be used
for children who have cards but lack evidence of the vac-
cination on their card.
Because children with cards were more likely to be vac-
cinated and their mothers were more likely to correctly re-
call MCV1 status, survey with higher card retention rates
may have less error in coverage estimates. Consequently,
we recommend that the card retention rates should always
be presented as an indicator of data quality when the
card + history indicator is used.
Our results should be interpreted in light of the limita-
tions of the data. Without a vaccination registry, there was
no gold standard measures of vaccination history or mea-
sles immunity [40]. We used strict criteria for matching
children with their EPI clinic records to avoid matching
errors, but this may have underestimated the number of
children with EPI records and induced a bias that overesti-
mated MCV1 coverage by EPI record. Results from OF
testing generated significant concern about its validity for
immunization surveillance. Several other studies have
shown good sensitivity and specificity for the assay, sug-
gesting that the problems in this study could be amelio-
rated [41-43].
Conclusions
This study illustrates that a simple comparison of data can
have broad implications for immunization surveillance.
Surveys using the card + history or maternal report indica-
tors combine feasibility with accuracy in this setting and
continued use is recommended to monitor secular trends
for MCV1 in Bangladesh. However, an equally accurate in-
dicator generated in real-time is needed and may be best
achieved by replacing EPI record books with electronic re-
cords to document a child’s vaccination history whereverthey get vaccinated. Given the low refusal rate for blood
collection in this study, other countries with inaccurate re-
ported or recorded vaccination indicators should consider
serological surveillance for measles antibodies as an alter-
native or corollary to existing surveillance tools. As coun-
tries like Bangladesh shift their focus from measles control
to elimination and eradication, serological surveillance to
estimate population immunity may become an increas-
ingly important indicator [44-46]. A careful consideration
of the costs and logistical challenges of serosurveillance
need to be weighed against the potential benefits of using
immune markers to monitor immunization systems.
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